NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $38,280 | -68.0% | 54,460 | +3.0% | 0.00% | -100.0% |
| Q4 2022 | $119,511 | -26.2% | 52,881 | +4.5% | 0.00% | -50.0% |
| Q3 2022 | $162,000 | -14.7% | 50,620 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $190,000 | -29.4% | 50,015 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $269,000 | -59.7% | 49,889 | +0.8% | 0.00% | -60.0% |
| Q4 2021 | $668,000 | -25.1% | 49,470 | -0.4% | 0.01% | -28.6% |
| Q3 2021 | $892,000 | +6.6% | 49,660 | +1.8% | 0.01% | 0.0% |
| Q2 2021 | $837,000 | -19.8% | 48,765 | -6.6% | 0.01% | -22.2% |
| Q1 2021 | $1,044,000 | +18.4% | 52,223 | +0.7% | 0.01% | +12.5% |
| Q4 2020 | $882,000 | -1.0% | 51,881 | -3.4% | 0.01% | -11.1% |
| Q3 2020 | $891,000 | -3.2% | 53,706 | +35.3% | 0.01% | -30.8% |
| Q2 2020 | $920,000 | +24.8% | 39,707 | -3.9% | 0.01% | 0.0% |
| Q1 2020 | $737,000 | -65.8% | 41,300 | -58.6% | 0.01% | -50.0% |
| Q4 2019 | $2,153,000 | +261.2% | 99,760 | +204.8% | 0.03% | +271.4% |
| Q3 2019 | $596,000 | -49.5% | 32,728 | -1.3% | 0.01% | -50.0% |
| Q2 2019 | $1,180,000 | -54.1% | 33,152 | -56.7% | 0.01% | -54.8% |
| Q1 2019 | $2,572,000 | +2.6% | 76,557 | +0.4% | 0.03% | -3.1% |
| Q4 2018 | $2,507,000 | -63.0% | 76,271 | -31.3% | 0.03% | -50.0% |
| Q3 2018 | $6,769,000 | +51.0% | 111,036 | +20.9% | 0.06% | +42.2% |
| Q2 2018 | $4,484,000 | +5.8% | 91,825 | +130.1% | 0.04% | +4.7% |
| Q1 2018 | $4,240,000 | -73.2% | 39,900 | -84.9% | 0.04% | -72.1% |
| Q4 2017 | $15,806,000 | +711.8% | 264,668 | +226.2% | 0.15% | +569.6% |
| Q3 2017 | $1,947,000 | +23.1% | 81,145 | +0.2% | 0.02% | +4.5% |
| Q2 2017 | $1,582,000 | -15.9% | 80,945 | +1.0% | 0.02% | -15.4% |
| Q1 2017 | $1,881,000 | +94.9% | 80,145 | +1.9% | 0.03% | +85.7% |
| Q4 2016 | $965,000 | -20.6% | 78,645 | +11.2% | 0.01% | -22.2% |
| Q3 2016 | $1,215,000 | +20.7% | 70,745 | 0.0% | 0.02% | +28.6% |
| Q2 2016 | $1,007,000 | +5.1% | 70,745 | +1.6% | 0.01% | +16.7% |
| Q1 2016 | $958,000 | -14.5% | 69,645 | +4.8% | 0.01% | -20.0% |
| Q4 2015 | $1,120,000 | +60.9% | 66,445 | +4.6% | 0.02% | +50.0% |
| Q3 2015 | $696,000 | – | 63,545 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |